These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22166407)

  • 1. Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease.
    Calandrella D; Antonini A
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S120-2. PubMed ID: 22166407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous dopaminergic delivery in Parkinson's disease.
    Antonini A; Ursino G; Calandrella D; Bernardi L; Plebani M
    J Neurol; 2010 Nov; 257(Suppl 2):S305-8. PubMed ID: 21080194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    Rascol O
    Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease.
    Antonini A; Chaudhuri KR; Martinez-Martin P; Odin P
    CNS Drugs; 2010 Feb; 24(2):119-29. PubMed ID: 20088619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease.
    Antonini A; Odin P
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S97-100. PubMed ID: 20123567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous dopaminergic stimulation--from theory to clinical practice.
    Antonini A
    Parkinsonism Relat Disord; 2007 Sep; 13 Suppl():S24-8. PubMed ID: 17702632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Olanow CW; Obeso JA; Stocchi F
    Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease.
    Antonini A; Mancini F; Canesi M; Zangaglia R; Isaias IU; Manfredi L; Pacchetti C; Zibetti M; Natuzzi F; Lopiano L; Nappi G; Pezzoli G
    Neurodegener Dis; 2008; 5(3-4):244-6. PubMed ID: 18322402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease.
    Nyholm D
    Expert Rev Neurother; 2006 Oct; 6(10):1403-11. PubMed ID: 17078781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
    Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study.
    Stocchi F; Vacca L; Ruggieri S; Olanow CW
    Arch Neurol; 2005 Jun; 62(6):905-10. PubMed ID: 15956161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors.
    Olanow CW; Obeso JA
    Neurology; 2000; 55(11 Suppl 4):S72-7; discussion S78-81. PubMed ID: 11147513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease.
    Wright BA; Waters CH
    Expert Rev Neurother; 2013 Jun; 13(6):719-29. PubMed ID: 23739008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
    Nyholm D; Constantinescu R; Holmberg B; Dizdar N; Askmark H
    Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease.
    Stocchi F
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S68-71. PubMed ID: 20083012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.
    Stacy M; Galbreath A
    Clin Neuropharmacol; 2008; 31(1):51-6. PubMed ID: 18303491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
    Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N
    Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ropinirole therapy for Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA
    Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.